Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-263550
Filing Date
2025-11-04
Accepted
2025-11-04 07:15:52
Documents
76
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kymr-20250930.htm   iXBRL 10-Q 3268813
2 EX-31.1 kymr-ex31_1.htm EX-31.1 18228
3 EX-31.2 kymr-ex31_2.htm EX-31.2 18100
4 EX-32.1 kymr-ex32_1.htm EX-32.1 10507
5 EX-32.2 kymr-ex32_2.htm EX-32.2 10382
  Complete submission text file 0001193125-25-263550.txt   12281227

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kymr-20250930.xsd EX-101.SCH 1551020
79 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20250930_htm.xml XML 2433600
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 251446441
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)